vs
NEOGENOMICS INC（NEO）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是NEOGENOMICS INC的1.1倍（$197.9M vs $186.7M），REPLIGEN CORP净利率更高（6.7% vs -57.9%，领先64.6%），REPLIGEN CORP同比增速更快（13.6% vs 11.1%），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 6.5%）
新基因组公司（NeoGenomics）是美国一家经CLIA认证的临床实验室企业，提供药企服务与信息服务，专注于癌症基因诊断检测，旗下检测服务涵盖细胞遗传学、荧光原位杂交（FISH）、流式细胞术、免疫组化、解剖病理学及分子遗传学等多个领域，为肿瘤相关诊断提供专业支持。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
NEO vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.1倍
$186.7M
营收增速更快
RGEN
高出2.6%
11.1%
净利率更高
RGEN
高出64.6%
-57.9%
两年增速更快
RGEN
近两年复合增速
6.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $186.7M | $197.9M |
| 净利润 | $-108.0M | $13.3M |
| 毛利率 | 43.3% | 52.5% |
| 营业利润率 | 46.9% | 9.0% |
| 净利率 | -57.9% | 6.7% |
| 营收同比 | 11.1% | 13.6% |
| 净利润同比 | 42.0% | 143.9% |
| 每股收益（稀释后） | $-0.13 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEORGEN
| Q1 26 | $186.7M | — | ||
| Q4 25 | $190.2M | $197.9M | ||
| Q3 25 | $187.8M | $188.8M | ||
| Q2 25 | $181.3M | $182.4M | ||
| Q1 25 | $168.0M | $169.2M | ||
| Q4 24 | $172.0M | $174.1M | ||
| Q3 24 | $167.8M | $154.9M | ||
| Q2 24 | $164.5M | $154.1M |
净利润NEORGEN
| Q1 26 | $-108.0M | — | ||
| Q4 25 | — | $13.3M | ||
| Q3 25 | $-27.1M | $14.9M | ||
| Q2 25 | $-45.1M | $14.9M | ||
| Q1 25 | $-25.9M | $5.8M | ||
| Q4 24 | — | $-30.3M | ||
| Q3 24 | $-17.7M | $-654.0K | ||
| Q2 24 | $-18.6M | $3.3M |
毛利率NEORGEN
| Q1 26 | 43.3% | — | ||
| Q4 25 | 43.8% | 52.5% | ||
| Q3 25 | 42.8% | 53.2% | ||
| Q2 25 | 42.6% | 50.0% | ||
| Q1 25 | 43.6% | 53.6% | ||
| Q4 24 | 44.9% | 26.1% | ||
| Q3 24 | 44.6% | 50.0% | ||
| Q2 24 | 44.1% | 49.8% |
营业利润率NEORGEN
| Q1 26 | 46.9% | — | ||
| Q4 25 | -7.1% | 9.0% | ||
| Q3 25 | -14.4% | 8.9% | ||
| Q2 25 | -26.3% | 7.6% | ||
| Q1 25 | -16.6% | 3.9% | ||
| Q4 24 | -10.7% | -17.7% | ||
| Q3 24 | -12.6% | -5.1% | ||
| Q2 24 | -13.3% | 1.0% |
净利率NEORGEN
| Q1 26 | -57.9% | — | ||
| Q4 25 | — | 6.7% | ||
| Q3 25 | -14.4% | 7.9% | ||
| Q2 25 | -24.9% | 8.2% | ||
| Q1 25 | -15.4% | 3.4% | ||
| Q4 24 | — | -17.4% | ||
| Q3 24 | -10.5% | -0.4% | ||
| Q2 24 | -11.3% | 2.2% |
每股收益（稀释后）NEORGEN
| Q1 26 | $-0.13 | — | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | $0.26 | ||
| Q2 25 | — | $0.26 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | — | $-0.55 | ||
| Q3 24 | — | $-0.01 | ||
| Q2 24 | — | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.1M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $828.8M | $2.1B |
| 总资产 | $1.3B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资NEORGEN
| Q1 26 | $146.1M | — | ||
| Q4 25 | $159.6M | $767.6M | ||
| Q3 25 | $164.1M | $748.7M | ||
| Q2 25 | $154.7M | $708.9M | ||
| Q1 25 | $346.2M | $697.2M | ||
| Q4 24 | $367.0M | $757.4M | ||
| Q3 24 | $362.0M | $784.0M | ||
| Q2 24 | $355.1M | $809.1M |
总债务NEORGEN
| Q1 26 | — | — | ||
| Q4 25 | $341.9M | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $541.1M | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益NEORGEN
| Q1 26 | $828.8M | — | ||
| Q4 25 | $836.6M | $2.1B | ||
| Q3 25 | $838.3M | $2.1B | ||
| Q2 25 | $854.0M | $2.1B | ||
| Q1 25 | $888.3M | $2.0B | ||
| Q4 24 | $902.3M | $2.0B | ||
| Q3 24 | $908.2M | $2.0B | ||
| Q2 24 | $915.9M | $2.0B |
总资产NEORGEN
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.4B | $2.9B | ||
| Q2 25 | $1.4B | $2.9B | ||
| Q1 25 | $1.6B | $2.9B | ||
| Q4 24 | $1.6B | $2.8B | ||
| Q3 24 | $1.6B | $2.8B | ||
| Q2 24 | $1.6B | $2.9B |
负债/权益比NEORGEN
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.60× | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.1M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流NEORGEN
| Q1 26 | $-8.1M | — | ||
| Q4 25 | $1.3M | $25.7M | ||
| Q3 25 | $8.9M | $48.1M | ||
| Q2 25 | $20.3M | $28.6M | ||
| Q1 25 | $-25.3M | $15.0M | ||
| Q4 24 | $9.8M | $39.2M | ||
| Q3 24 | $9.2M | $49.3M | ||
| Q2 24 | $13.9M | $42.2M |
自由现金流NEORGEN
| Q1 26 | — | — | ||
| Q4 25 | $-6.5M | $17.6M | ||
| Q3 25 | $570.0K | $43.4M | ||
| Q2 25 | $14.0M | $21.5M | ||
| Q1 25 | $-29.8M | $11.4M | ||
| Q4 24 | $-1.8M | $33.6M | ||
| Q3 24 | $-1.6M | $42.3M | ||
| Q2 24 | $814.0K | $37.4M |
自由现金流率NEORGEN
| Q1 26 | — | — | ||
| Q4 25 | -3.4% | 8.9% | ||
| Q3 25 | 0.3% | 23.0% | ||
| Q2 25 | 7.7% | 11.8% | ||
| Q1 25 | -17.8% | 6.8% | ||
| Q4 24 | -1.0% | 19.3% | ||
| Q3 24 | -0.9% | 27.3% | ||
| Q2 24 | 0.5% | 24.3% |
资本支出强度NEORGEN
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 4.1% | ||
| Q3 25 | 4.4% | 2.5% | ||
| Q2 25 | 3.5% | 3.9% | ||
| Q1 25 | 2.7% | 2.1% | ||
| Q4 24 | 6.7% | 3.2% | ||
| Q3 24 | 6.4% | 4.5% | ||
| Q2 24 | 8.0% | 3.1% |
现金转化率NEORGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
